Complicaciones de la colocación de malla sintética vaginal para la incontinencia urinaria de esfuerzo

ResumenAntecedentesLas mallas para la incontinencia urinaria (IU) se han utilizado a pesar de la falta de evidencia de nivel i en la literatura para evaluar su seguridad y eficacia a largo plazo. Las complicaciones relacionadas con la malla provocaron una advertencia emitida por la FDA en 2008 y dejaron de ser consideradas eventos raros. Las complicaciones más comunes son la retención aguda de orina, sangrado, recurrencia o persistencia de la IU, erosión de uretra e infección de la malla.ObjetivoConocer cuáles son las complicaciones derivadas del tratamiento quirúrgico de la IU femenina con la colocación de mallas suburetrales.Material y métodoSe analizaron los pacientes con diagnóstico de IU operadas con cirugía antiincontinencia y colocación de malla vaginal del año 2007 al 2014. Se analizó las complicaciones derivadas de la colocación de malla y la recuperación de continencia.ResultadosA 58 pacientes se les colocó sling (cabestrillo) con malla sintética; edad promedio de 56 años. El 51% de las pacientes tenían IU de esfuerzo y el 49% IU mixta. Las complicaciones tempranas fueron: 4 pacientes con retención aguda de orina. Las complicaciones tardías: dolor uretral o vaginal (12.2%), dispareunia (20%) y extrusión de malla (10%) manejado con retiro de la misma, 2 de ellas requiriendo 2 procedimientos quirúrgicos. El 12% presentaron urgencia de novo, el 90.2% evolucionaron sin incontinencia, el 9.7% con IU postoperatoria y 2 pacientes sin mejoría.DiscusiónNuestra serie, aunque pequeña, muestra una baja tasa de complicaciones a largo plazo relacionadas con la malla en comparación con la mayoría de las series que muestran una tasa de reoperación de hasta>70% y con múltiples casos de retiro de malla, por lo que en nuestra experiencia los slings suburetrales continúan siendo una opción adecuada en el manejo de la IU.ConclusionesLos slings suburetrales son una opción segura y efectiva en el manejo de la IU.AbstractBackgroundSurgical mesh has been used for treating urinary incontinence (UI) despite the lack of level i evidence in the literature evaluating its long-term safety and efficacy. Mesh-related complications were responsible for a warning issued by the FDA in 2008 and they stopped being considered rare events. The most common complications are acute urinary retention, bleeding, recurrence or persistence of UI, erosion of the urethra, and mesh infection.AimsTo determine the complications derived from surgical UI treatment with the placement of suburethral mesh in women.Material and methodPatients diagnosed with UI that underwent anti-incontinence surgery with the placement of vaginal mesh within the time frame of 2007 and 2014 were analyzed. Mesh placement complications and the recovery of continence were evaluated.ResultsA synthetic mesh sling was placed in 58 patients with a mean age of 56 years. A total of 51% of the patients had stress urinary incontinence and 49% had mixed urinary incontinence. Early complications were: 4 patients with acute urine retention. Late complications were: urethral or vaginal pain (12.2%), dyspareunia (20%), and mesh extrusion (10%) that was managed through mesh removal; 2 of those patients required surgical procedures. Twelve percent of the patients presented with de novo urgency, 90.2% progressed with no incontinence, 9.7% presented with postoperative UI, and 2 patients had no improvement.DiscussionAlthough small, our case series showed a low long-term complication rate with the use of surgical mesh, compared with the majority of case series that demonstrate a re-operation rate>70%, as well as numerous cases of mesh removal. Thus, it is our experience that suburethral slings continue to be an adequate UI management option.ConclusionsSuburethral slings are a safe and effective option in UI management

The Antiretroviral Lectin Cyanovirin-N Targets Well-Known and Novel Targets on the Surface of Entamoeba histolytica Trophozoites ▿ †

Entamoeba histolytica, the protist that causes amebic dysentery and liver abscess, has a truncated Asn-linked glycan (N-glycan) precursor composed of seven sugars (Man5GlcNAc2). Here, we show that glycoproteins with unmodified N-glycans are aggregated and capped on the surface of E. histolytica trophozoites by the antiretroviral lectin cyanovirin-N and then replenished from large intracellular pools. Cyanovirin-N cocaps the Gal/GalNAc adherence lectin, as well as glycoproteins containing O-phosphodiester-linked glycans recognized by an anti-proteophosphoglycan monoclonal antibody. Cyanovirin-N inhibits phagocytosis by E. histolytica trophozoites of mucin-coated beads, a surrogate assay for amebic virulence. For technical reasons, we used the plant lectin concanavalin A rather than cyanovirin-N to enrich secreted and membrane proteins for mass spectrometric identification. E. histolytica glycoproteins with occupied N-glycan sites include Gal/GalNAc lectins, proteases, and 17 previously hypothetical proteins. The latter glycoproteins, as well as 50 previously hypothetical proteins enriched by concanavalin A, may be vaccine targets as they are abundant and unique. In summary, the antiretroviral lectin cyanovirin-N binds to well-known and novel targets on the surface of E. histolytica that are rapidly replenished from large intracellular pools

Drug Targets and Mechanisms of Resistance in the Anaerobic Protozoa

The anaerobic protozoa Giardia duodenalis, Trichomonas vaginalis, and Entamoeba histolytica infect up to a billion people each year. G. duodenalis and E. histolytica are primarily pathogens of the intestinal tract, although E. histolytica can form abscesses and invade other organs, where it can be fatal if left untreated. T. vaginalis infection is a sexually transmitted infection causing vaginitis and acute inflammatory disease of the genital mucosa. T. vaginalis has also been reported in the urinary tract, fallopian tubes, and pelvis and can cause pneumonia, bronchitis, and oral lesions. Respiratory infections can be acquired perinatally. T. vaginalis infections have been associated with preterm delivery, low birth weight, and increased mortality as well as predisposing to human immunodeficiency virus infection, AIDS, and cervical cancer. All three organisms lack mitochondria and are susceptible to the nitroimidazole metronidazole because of similar low-redox-potential anaerobic metabolic pathways. Resistance to metronidazole and other drugs has been observed clinically and in the laboratory. Laboratory studies have identified the enzyme that activates metronidazole, pyruvate:ferredoxin oxidoreductase, to its nitroso form and distinct mechanisms of decreasing drug susceptibility that are induced in each organism. Although the nitroimidazoles have been the drug family of choice for treating the anaerobic protozoa, G. duodenalis is less susceptible to other antiparasitic drugs, such as furazolidone, albendazole, and quinacrine. Resistance has been demonstrated for each agent, and the mechanism of resistance has been investigated. Metronidazole resistance in T. vaginalis is well documented, and the principal mechanisms have been defined. Bypass metabolism, such as alternative oxidoreductases, have been discovered in both organisms. Aerobic versus anaerobic resistance in T. vaginalis is discussed. Mechanisms of metronidazole resistance in E. histolytica have recently been investigated using laboratory-induced resistant isolates. Instead of downregulation of the pyruvate:ferredoxin oxidoreductase and ferredoxin pathway as seen in G. duodenalis and T. vaginalis, E. histolytica induces oxidative stress mechanisms, including superoxide dismutase and peroxiredoxin. The review examines the value of investigating both clinical and laboratory-induced syngeneic drug-resistant isolates and dissection of the complementary data obtained. Comparison of resistance mechanisms in anaerobic bacteria and the parasitic protozoa is discussed as well as the value of studies of the epidemiology of resistance